SchrodingerSDGR
SDGR
About: Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.
Employees: 787
0
Funds holding %
of 6,831 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
89% more call options, than puts
Call options by funds: $14.2M | Put options by funds: $7.55M
3% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 32
0% less funds holding
Funds holding: 205 [Q2] → 204 (-1) [Q3]
2.17% less ownership
Funds ownership: 96.87% [Q2] → 94.7% (-2.17%) [Q3]
6% less capital invested
Capital invested by funds: $1.19B [Q2] → $1.12B (-$72.3M) [Q3]
13% less repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 72
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$27
9%
upside
Avg. target
$28
11%
upside
High target
$28
13%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Keybanc Scott Schoenhaus 39% 1-year accuracy 14 / 36 met price target | 9%upside $27 | Overweight Maintained | 24 Jan 2025 |
BMO Capital Gary Nachman 62% 1-year accuracy 8 / 13 met price target | 14%upside $28 | Outperform Maintained | 13 Nov 2024 |
Financial journalist opinion
Based on 3 articles about SDGR published over the past 30 days
Positive
Zacks Investment Research
3 days ago
Schrodinger (SDGR) Moves 14.1% Higher: Will This Strength Last?
Schrodinger (SDGR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Neutral
Business Wire
4 days ago
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on January 20, 2025, the company granted restricted stock units (RSUs) with respect to 4,840 shares of the company's common stock to four newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement.
Neutral
Business Wire
1 week ago
Schrödinger Provides Update on Progress Across the Business and Outlines 2025 Strategic Priorities
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today provided an update on its progress across the business in 2024 and announced its strategic priorities for 2025. “We are very proud of our accomplishments in 2024. We advanced the capabilities of our computational platform and leveraged the synergies in our business, which included signing a multi-target research collaboration and expanded software licensing agreement with Novartis. We are pleased another innovative pharmaceutical.
Neutral
Business Wire
1 month ago
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on December 12, 2024, the company granted restricted stock units (RSUs) with respect to 8,365 shares of the company's common stock to six newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement.
Neutral
Business Wire
2 months ago
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on November 14, 2024, the company granted restricted stock units (RSUs) with respect to 2,785 shares of the company's common stock to four newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducemen.
Neutral
Business Wire
2 months ago
Schrödinger Broadens and Accelerates Predictive Toxicology Initiative
NEW YORK--(BUSINESS WIRE)--Schrödinger broadens and accelerates predictive toxicology initiative.
Neutral
Seeking Alpha
2 months ago
Schrödinger (SDGR) Q3 2024 Earnings Call Transcript
Schrödinger Inc. (NASDAQ:SDGR ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Ramy Farid - President, Chief Executive Officer Karen Akinsanya - President, R&D and Therapeutics Geoff Porges - Chief Financial Officer Jaren Madden - Senior Vice President, Corporate Affairs and Investor Relations Conference Call Participants Matt - Jefferies Mani Foroohar - Leerink Partners Steve - Keybanc Gaspa - Morgan Stanley Evan Seigerman - BMO Capital Markets Joe Catanzaro - Piper Sandler Toff - Craig Hallum Brendan Smith - TD Cowen Sean Kim - Bank of America John - Citi Operator Welcome to Schrödinger's conference call to review our third quarter 2024 financial results. My name is Madison and I will be your Operator for today's call.
Negative
Zacks Investment Research
2 months ago
Schrodinger, Inc. (SDGR) Reports Q3 Loss, Misses Revenue Estimates
Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.86 per share a year ago.
Neutral
Business Wire
2 months ago
Schrödinger Reports Third Quarter 2024 Financial Results
NEW YORK--(BUSINESS WIRE)--Schrödinger today announced financial results for the third quarter of 2024 and provided a business update.
Neutral
Business Wire
2 months ago
Schrödinger to Present at Jefferies London Healthcare Conference
NEW YORK--(BUSINESS WIRE)--Schrödinger today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference.
Charts implemented using Lightweight Charts™